Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $16.25 USD
Change Today +0.09 / 0.56%
Volume 370.4K
AQXP On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

aquinox pharmaceuticals inc (AQXP) Snapshot

Open
$16.00
Previous Close
$16.16
Day High
$16.42
Day Low
$15.60
52 Week High
08/10/15 - $55.75
52 Week Low
07/27/15 - $1.38
Market Cap
174.3M
Average Volume 10 Days
494.1K
EPS TTM
$-2.43
Shares Outstanding
10.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AQUINOX PHARMACEUTICALS INC (AQXP)

Related News

No related news articles were found.

aquinox pharmaceuticals inc (AQXP) Related Businessweek News

No Related Businessweek News Found

aquinox pharmaceuticals inc (AQXP) Details

Aquinox Pharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in discovering and developing targeted therapeutics for diseases in the areas of inflammation and immuno-oncology. The company primarily focuses on anti-inflammatory product candidates targeting SHIP1, a key regulator of a cellular signaling pathway in immune cells. Its lead product candidate is AQX-1125, a small molecule activator of SHIP1 that is in Phase II clinical trials for chronic obstructive pulmonary disease, bladder pain syndrome/interstitial cystitis, and atopic dermatitis. The company was formerly known as 6175813 Canada Inc. and changed its name to Aquinox Pharmaceuticals Inc. in March 2006. Aquinox Pharmaceuticals Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

24 Employees
Last Reported Date: 08/6/15
Founded in 2003

aquinox pharmaceuticals inc (AQXP) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $365.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $181.1K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $302.4K
Compensation as of Fiscal Year 2014.

aquinox pharmaceuticals inc (AQXP) Key Developments

Aquinox Pharmaceuticals Inc. Announces Results from Trial with AQX-1125 in Chronic Obstructive Pulmonary Disease Patients with Frequent Exacerbations

Aquinox Pharmaceuticals Inc. announced its Phase 2 clinical trial failed to demonstrate efficacy in chronic obstructive pulmonary disease patients with a history of frequent exacerbations. In the trial, patients treated with 200 mg oral, once daily AQX-1125 for 12 weeks demonstrated no difference in COPD symptoms compared to placebo, as measured by EXACT, a patient-reported outcome tool. On the secondary endpoint of medically treated exacerbations there was also no benefit observed with AQX-1125.

Aquinox Pharmaceuticals Inc. Announces Results from LEADERSHIP Trial with AQX-1125 in Patients with Bladder Pain Syndrome/Interstitial Cystitis

Aquinox Pharmaceuticals Inc. announced results from its Phase 2 LEADERSHIP randomized clinical trial investigating the therapeutic potential of AQX-1125 in treating pain in patients with bladder pain syndrome/interstitial cystitis. While AQX-1125 demonstrated a reduction in pain for patients on AQX-1125 as compared to those patients on placebo following six weeks of treatment, the difference did not reach statistical significance.

Aquinox Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Announces Positive Results from Secondary Endpoints from Phase 2 LEADERSHIP Trial in BPS/IC

Aquinox Pharmaceuticals Inc. announced results from secondary endpoints from its Phase 2 LEADERSHIP trial with AQX-1125 in patients with bladder pain syndrome/interstitial cystitis (BPS/IC). Consistently positive results from multiple secondary endpoints have strengthened its confidence in further development of AQX-1125 for BPS/IC. The encouraging effect of AQX-1125 observed on the primary endpoint of reduction in pain together with several statistically significant secondary endpoints, underscore the potential of AQX-1125 as a once daily, oral therapy for this debilitating disease. The company reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, net loss was $4.8 million compared to a net loss of $5.4 million for the second quarter of 2014. This decline in net loss reflected the decrease in research and development expenses. Net loss before income taxes was $4.750 million against $5.424 million a year ago. Net loss per common stock - basic and diluted was $0.44 against $0.51 a year ago. For the six months, the company reported net loss before income taxes of $11.162 million against $9.653 million a year ago. Net loss was $11.162 million or $1.04 per basic and diluted share against $9.653 million or $1.43 per basic and diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AQXP:US $16.25 USD +0.09

AQXP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AQXP.
View Industry Companies
 

Industry Analysis

AQXP

Industry Average

Valuation AQXP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 6.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AQUINOX PHARMACEUTICALS INC, please visit www.aqxpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.